LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...

In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

AstraZeneca chief Pascal Soriot has said a deepening criminal probe into his company’s Chinese business is being taken “very ...

Following mixed study results, the partners have backed away from seeking broad clearance of dato-dxd in lung cancer and ...

Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...

“TROPION-Lung01 was designed to test the potential to improve upon standard-of-care chemotherapy in a broad, previously ...

AstraZeneca (AZN) and Daiichi Sankyo have submitted a new ... with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer who have received prior systemic ...

AstraZeneca now expects 2024 revenue and core earnings per share to grow by a high-teens percentage, from a previous forecast ...

The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...

Datopotamab deruxtecan new BLA submitted for accelerated approval in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer AstraZeneca and Daiichi Sankyo's new ...